| Xiong, Bin |
RESCUE-GC, NCT02867839: Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer |
|
|
| Terminated | 3 | 29 | RoW | Oxaliplatin plus S-1, SOX, S-1 only, S-1 | Peking University Cancer Hospital & Institute | Gastric Cancer | 09/21 | 09/21 | | |
NCT04909866: The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study |
|
|
| Recruiting | 2/3 | 40 | RoW | TACE+Lenvatininb+Camrelizumab | Wuhan Union Hospital, China | Hepatocellular Carcinoma | 09/22 | 12/22 | | |
NCT04345770: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 100 | RoW | D2 radical gastrectomy, Surgery, SOX neoadjuvant or postoperative chemotherapy, Chemotherapy, Hyperthermic intraperitoneal chemotherapy (HIPEC), HIPEC | Wuhan University | Malignant Neoplasm of Stomach | 03/25 | 05/25 | | |
NCT06484764: Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Biopsy Procedure. |
|
|
| Completed | N/A | 166 | RoW | CT-fluoroscopy guided robot-assisted biopsy of thoracic and abdominal lesions, Freehand CT-guided percutaneous needle biopsy of thoracic and abdominal lesions | Tianjin Medical University Cancer Institute and Hospital, Tongji Hospital, The First Affiliated Hospital of Guangzhou Medical University, Wuhan United Imaging Healthcare-Surgical Technology Co., Ltd. Wuhan, China | Abdominal Cancer, Thoracic Cancer | 10/23 | 11/23 | | |
NCT06496919: A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors |
|
|
| Not yet recruiting | N/A | 300 | RoW | Recombinant Mutant Human Tumor Necrosis Factor | Wuhan University | Gastric Cancer | 07/26 | 07/27 | | |
NCT06464601: A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer |
|
|
| Not yet recruiting | N/A | 70 | RoW | fruquintinib combined with immune checkpoint inhibitors and chemotherapy | Wuhan University | Gastric Cancer | 03/26 | 03/27 | | |
NCT06470178: A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents |
|
|
| Not yet recruiting | N/A | 70 | RoW | corhot1: chemotherapy combined with fruquintinib, corhot2: chemotherapy combined with fruquintinib | Wuhan University | Colorectal Cancer | 04/26 | 04/27 | | |
NCT06117735: Clinical Study of PTFE Covered Stent for Treating Portal Hypertension |
|
|
| Recruiting | N/A | 177 | RoW | Transjugular Intrahepatic Portosystemic shunt | Enlight Medical Technologies (Shanghai) Co., Ltd | Portal Hypertension | 12/25 | 06/26 | | |
| Wang, Fei |
NCT06269445: The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer |
|
|
| Recruiting | 4 | 20 | RoW | Icaritin Combined With Bevacizumab and FOLFIRI | Sir Run Run Shaw Hospital | Colorectal Cancer | 02/25 | 02/26 | | |
NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
|
|
| Recruiting | 3 | 256 | US, RoW | Afuresertib, Fulvestrant, Afuresertib/placebo | Laekna Limited | Breast Cancer | 10/26 | 12/26 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT05369078: Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects |
|
|
| Recruiting | 1 | 16 | RoW | THR-1442 20mg Single dose, THR-1442 20mg Multiple dose group | Newsoara Biopharma Co., Ltd. | T2DM (Type 2 Diabetes Mellitus) | 05/22 | 05/22 | | |
NCT06561997: Enhancing Thoracolumbar Burst Fracture Treatment |
|
|
| Completed | N/A | 182 | RoW | Robot-assisted, Free-hand | Peng Liu | Surgery | 06/19 | 06/20 | | |
FLAT, NCT03805191: A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients |
|
|
| Recruiting | N/A | 900 | RoW | | Qilu Hospital of Shandong University, Bayer | Type 2 Diabetes Mellitus, Poor Glycemic Control | 11/20 | 12/22 | | |
NCT04658992: The Registration on the Use of Feilike Heji in Minors |
|
|
| Recruiting | N/A | 3000 | RoW | | China Academy of Chinese Medical Sciences | Bronchial Asthma | 12/21 | 03/22 | | |
NCT05949736: Effect of Music Therapy in Medical Students (EMTMS) |
|
|
| Recruiting | N/A | 200 | RoW | The Online intervention platform | Jiangsu Province Nanjing Brain Hospital | Depression, Anxiety, Insomnia | 08/23 | 05/25 | | |
| Recruiting | N/A | 60 | RoW | Group Cognitive Behavioral Therapy (GCBT) | Jiangsu Province Nanjing Brain Hospital | Mental Suffering | 09/23 | 01/24 | | |
NCT05648539: Effect of Music Therapy in Mental Subhealth (EMTMS) |
|
|
| Recruiting | N/A | 150 | RoW | The mini apps named "SOUL GYM" on the Wechat | Jiangsu Province Nanjing Brain Hospital | Depression, Anxiety | 10/23 | 10/27 | | |
| Recruiting | N/A | 120 | RoW | Active rTMS, VISHEE Magneuro stimulator, Sham rTMS | Jiangsu Province Nanjing Brain Hospital | Major Depressive Episode | 07/24 | 07/24 | | |
NCT06238869: Online Mental Health Interventions for Children and Adolescents (OMHICA) |
|
|
| Enrolling by invitation | N/A | 7000 | RoW | Computerized Cognitive Behavioral Therapy, Music Therapy, Health education | Jiangsu Province Nanjing Brain Hospital | Depression, Anxiety, Stress, Insomnia | 09/25 | 12/25 | | |
NCT05681364: Prediction of Pulmonary Rehabilitation Outcomes in Patients With Chronic Respiratory Disease Based on Metabolomics: a Prospective Cohort Study |
|
|
| Not yet recruiting | N/A | 300 | NA | metabonomics | Peking University Third Hospital | Chronic Obstructive Pulmonary Disease, Bronchiectasis | 12/24 | 12/24 | | |
PRHDTDCSTMDE, NCT05498441: Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Treatment for Major Depressive Episode |
|
|
| Recruiting | N/A | 120 | RoW | High-Definition Transcranial Direct Current Stimulation (HD-tDCS), Antipsychotics, mood stabilizers, etc. | Jiangsu Province Nanjing Brain Hospital | Major Depressive Episode | 12/24 | 12/24 | | |
NCT05774288: Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders. |
|
|
| Recruiting | N/A | 244 | RoW | Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders | Lifetech Scientific (Shenzhen) Co., Ltd. | Patent Foramen Ovale, Cryptogenic Stroke | 04/25 | 06/29 | | |
| Tao, Weiping |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
NCT04600947: Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 69 | RoW | LP002 | Taizhou HoudeAoke Biomedical Co., Ltd. | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | 05/22 | 05/23 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
|
|
| Withdrawn | 2 | 177 | RoW | Balstilimab, Balstilimab + Zalifrelimab | Agenus Inc., Betta Pharmaceuticals Co., Ltd. | Cervical Cancer | 12/24 | 12/24 | | |
